Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer.
1/5 보강
Despite advances in breast cancer therapy, effective treatment options remain a challenge.
APA
Safaei M, Li YC, et al. (2026). Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer.. Cancer letters, 639, 218225. https://doi.org/10.1016/j.canlet.2025.218225
MLA
Safaei M, et al.. "Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer.." Cancer letters, vol. 639, 2026, pp. 218225.
PMID
41423054 ↗
Abstract 한글 요약
Despite advances in breast cancer therapy, effective treatment options remain a challenge. The Ephrin receptor A10 (EphA10), a receptor tyrosine kinase, has been reported to be overexpressed in several cancers, including breast and ovarian cancers yet absent in the majority of normal cells except for the male testis. This unique expression profile makes EphA10 an ideal therapeutic target for cancers in women. However, effective EphA10-directed therapies have yet to be developed. To investigate the therapeutic potential of targeting EphA10, we evaluated an antibody drug conjugate strategy. For this purpose, chimeric and humanized EphA10 antibodies were generated and conjugated with monomethyl auristatin E (MMAE). The results showed that EphA10-MMAE exhibited strong cytotoxic effects against EphA10-positive breast cancer cells, including those resistant to FDA-approved drugs such as trastuzumab, lapatinib, PARP inhibitors, and cyclin-dependent kinases 4 and 6 inhibitors. Taken together, these findings highlight EphA10-MMAE as a promising therapeutic strategy for breast cancer, with the potential to overcome drug resistance to existing treatments.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.